vs

Side-by-side financial comparison of STAK Inc. (STAK) and Verastem, Inc. (VSTM). Click either name above to swap in a different company.

STAK Inc. is the larger business by last-quarter revenue ($13.6M vs $11.2M, roughly 1.2× Verastem, Inc.). STAK Inc. runs the higher net margin — 11.9% vs -876.3%, a 888.2% gap on every dollar of revenue.

Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

STAK vs VSTM — Head-to-Head

Bigger by revenue
STAK
STAK
1.2× larger
STAK
$13.6M
$11.2M
VSTM
Higher net margin
STAK
STAK
888.2% more per $
STAK
11.9%
-876.3%
VSTM

Income Statement — Q4 FY2024 vs Q3 FY2025

Metric
STAK
STAK
VSTM
VSTM
Revenue
$13.6M
$11.2M
Net Profit
$1.6M
$-98.5M
Gross Margin
28.5%
Operating Margin
13.6%
-362.2%
Net Margin
11.9%
-876.3%
Revenue YoY
Net Profit YoY
-311.1%
EPS (diluted)
$-1.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
STAK
STAK
VSTM
VSTM
Q3 25
$11.2M
Q2 25
$2.1M
Q4 24
$13.6M
Q3 24
$0
Q2 24
$10.0M
Net Profit
STAK
STAK
VSTM
VSTM
Q3 25
$-98.5M
Q2 25
$-25.9M
Q4 24
$1.6M
Q3 24
$-24.0M
Q2 24
$-8.3M
Gross Margin
STAK
STAK
VSTM
VSTM
Q3 25
Q2 25
Q4 24
28.5%
Q3 24
Q2 24
Operating Margin
STAK
STAK
VSTM
VSTM
Q3 25
-362.2%
Q2 25
-2047.9%
Q4 24
13.6%
Q3 24
Q2 24
-182.8%
Net Margin
STAK
STAK
VSTM
VSTM
Q3 25
-876.3%
Q2 25
-1213.6%
Q4 24
11.9%
Q3 24
Q2 24
-82.6%
EPS (diluted)
STAK
STAK
VSTM
VSTM
Q3 25
$-1.35
Q2 25
$-0.62
Q4 24
Q3 24
$-0.60
Q2 24
$-0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
STAK
STAK
VSTM
VSTM
Cash + ST InvestmentsLiquidity on hand
$658.2K
$137.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$10.6M
$-15.5M
Total Assets
$18.8M
$176.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
STAK
STAK
VSTM
VSTM
Q3 25
$137.7M
Q2 25
$164.3M
Q4 24
$658.2K
Q3 24
$113.2M
Q2 24
$83.4M
Total Debt
STAK
STAK
VSTM
VSTM
Q3 25
Q2 25
Q4 24
Q3 24
$40.5M
Q2 24
$40.3M
Stockholders' Equity
STAK
STAK
VSTM
VSTM
Q3 25
$-15.5M
Q2 25
$36.1M
Q4 24
$10.6M
Q3 24
$11.1M
Q2 24
$18.9M
Total Assets
STAK
STAK
VSTM
VSTM
Q3 25
$176.9M
Q2 25
$196.3M
Q4 24
$18.8M
Q3 24
$126.4M
Q2 24
$105.7M
Debt / Equity
STAK
STAK
VSTM
VSTM
Q3 25
Q2 25
Q4 24
Q3 24
3.66×
Q2 24
2.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
STAK
STAK
VSTM
VSTM
Operating Cash FlowLast quarter
$-998.6K
$-36.2M
Free Cash FlowOCF − Capex
$-1.0M
FCF MarginFCF / Revenue
-7.4%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
-0.62×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
STAK
STAK
VSTM
VSTM
Q3 25
$-36.2M
Q2 25
$-32.7M
Q4 24
$-998.6K
Q3 24
$-23.8M
Q2 24
$-27.6M
Free Cash Flow
STAK
STAK
VSTM
VSTM
Q3 25
Q2 25
Q4 24
$-1.0M
Q3 24
Q2 24
$-27.6M
FCF Margin
STAK
STAK
VSTM
VSTM
Q3 25
Q2 25
Q4 24
-7.4%
Q3 24
Q2 24
-275.8%
Capex Intensity
STAK
STAK
VSTM
VSTM
Q3 25
Q2 25
Q4 24
0.0%
Q3 24
Q2 24
0.1%
Cash Conversion
STAK
STAK
VSTM
VSTM
Q3 25
Q2 25
Q4 24
-0.62×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

STAK
STAK

Other$4.2M31%
Sales of specialized oilfield equipment$4.0M30%
Total$3.3M24%
Sales of specialized oilfield vehicle$2.1M15%
Service income from automation solutions$26.4K0%

VSTM
VSTM

Segment breakdown not available.

Related Comparisons